Open AccessBarriers to Contraceptive Use in Product Labeling and Practice Guidelines
Author(s) -
Daniel Grossman,
Charlotte Ellertson,
Katrina Abuabara,
Kelly Blanchard,
Francisco T. Rivas
Publication year - 2006
Publication title -
american journal of public health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.284
H-Index - 264
eISSN - 1541-0048
pISSN - 0090-0036
DOI - 10.2105/ajph.2004.040774
Subject(s) - medicine , medical prescription , family planning , developed country , developing country , family medicine , package insert , product (mathematics) , environmental health , population , research methodology , nursing , economic growth , pharmacology , economics , geometry , mathematics
Many contraceptives are encumbered with potentially unnecessary restrictions on their use. Indeed, fear of side effects, fostered by alarmist labeling, is a leading reason that women do not use contraceptives. In the United States, hormonal methods currently require a prescription, although research suggests that women can adequately screen themselves for contraindications, manage side effects, and determine an appropriate initiation date, leaving little need for routine direct physician involvement. Sizing, spermicidal use, and length-of-wear limits burden users of cervical barriers and may be unnecessary. Despite recent changes in the labeling of intrauterine devices, clinicians commonly restrict use of this method and in some countries may limit the types of providers authorized to insert them. Although in some cases additional research is necessary, existing data indicate that evidence-based demedicalization of contraceptive provision could reduce costs and improve access.